Mirodenafil

DB11792InvestigationalSmall molecule

Mirodenafil has been used in trials studying the treatment and supportive care of Kidney Diseases, Urologic Diseases, Renal Insufficiency, Erectile Dysfunction, and Male Erectile Dysfunction.

Mechanism: Pharmacologically active on cGMP-specific 3',5'-cyclic phosphodiesterase
Curator reviewed
Formula / weight: C₂₆H₃₇N₅O₅S · 531.67 g/mol (avg)
Code names: AR1001 · SK-3530

Resolves to

Compound

UNII504G362H0HCAS862189-95-5PubChem12001014

Structure

InChIKeyMIJFNYMSCFYZNY-UHFFFAOYSA-NSMILESCCCOC1=CC=C(C=C1C1=NC2=C(N(CC)C=C2CCC)C(=O)N1)S(=O)(=O)N1CCN(CCO)CC1

Targets

O76074PDE5AP04150NR3C1

What you can answer from here — as of July 07, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

323Drug interactionsStructured to mechanism, not free text

8Clinical trialsPhase, status and sponsor resolved per trial

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with Mirodenafil, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account